

IN THE ABSTRACT:

Please replace the abstract paragraph beginning at page 129, line 5 with the following rewritten paragraph:

C39 -- The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is over-expressed across all stages of prostate cancer, bladder cancer, pancreatic cancer, and bone metastasis of prostate cancer. Various embodiments of antibodies specific to PSCA are provided, including antibody fragments, immunoconjugates, internalizing antibodies, chimeric antibodies, human antibodies, and hybridomas which produce the anti-PSCA antibodies. -- .

REMARKS

This is a third amendment submitted in connection with the above-referenced patent application. The first amendment was submitted in a Preliminary amendment, dated January 12, 2000, in which the specification was amended by adding sequence listing indicators (e.g., SEQ ID NO:). The second amendment was submitted on August 11, 2000, in which applicants elected claim 1-6 and 8-11, cancelled claim 8, and amended claims 1-6 and 9-11.

Claims 1-6 and 9-17 were pending. Claims 1-3 are amended herein. Claims 4-6 and 9-17 are cancelled without prejudice. New claims 18-35 are added herein. Accordingly, claims 1-3 and 18-35 are now being examined.

Support for amended claims 1, 2, and 3 can be found in the originally-filed specification of 09/038,261 at page 13, lines 24-26; Example 5 at pages 35-36; and Example 6 at pages 36-38.

Support for new claims 18 and 19 can be found in the originally-filed specification of 09/038,261 at page 13, lines 29-31.